STOCK TITAN

Repare Therapeutics to Participate at the Goldman Sachs 43rd Annual Global Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Repare Therapeutics Inc. (Nasdaq: RPTX), a clinical-stage precision oncology company, announced participation in a fireside chat at the Goldman Sachs 43rd Annual Global Healthcare Conference on June 14, 2022, at 03:20 p.m. PT. The event will take place in Rancho Palos Verdes, CA. A live webcast will be available on the Company’s website, with an archived replay for 90 days. Repare specializes in cancer therapies using its SNIPRx® platform, focusing on genomic instability and DNA damage repair, and is currently developed leading products like camonsertib (RP-3500) and RP-6306.

Positive
  • None.
Negative
  • None.

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)-- Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced that members of its senior management team will participate in a fireside chat at the Goldman Sachs 43rd Annual Global Healthcare Conference on Tuesday, June 14, 2022 at 03:20 p.m. Pacific Time/ 6:20 p.m. Eastern Time in Rancho Palos Verdes, CA.

A live webcast of the fireside chat can be accessed in the Investor section of the Company’s website at https://ir.reparerx.com/news-and-events/events. A replay of the webcast will be archived on the Company’s website for 90 days.

About Repare Therapeutics, Inc.

Repare Therapeutics is a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx® platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. The Company’s pipeline includes its lead product candidate camonsertib (also known as RP-3500), a potential leading ATR inhibitor currently in Phase 1/2 clinical development, its second clinical candidate, RP-6306, a PKMYT1 inhibitor currently in Phase 1 clinical development, a Polθ inhibitor program, as well as several early-stage, pre-clinical programs. For more information, please visit reparerx.com.

SNIPRx® is a registered trademark of Repare Therapeutics Inc.

Repare Contact:

Steve Forte

Chief Financial Officer

Repare Therapeutics Inc.

info@reparerx.com

Investors:

Kimberly Minarovich

Argot Partners

repare@argotpartners.com

Media:

David Rosen

Argot Partners

david.rosen@argotpartners.com

212-600-1902

Source: Repare Therapeutics Inc.

FAQ

What is the date and time of Repare Therapeutics' fireside chat at the Goldman Sachs Global Healthcare Conference?

Repare Therapeutics will participate in the fireside chat on June 14, 2022, at 03:20 p.m. Pacific Time.

Where will the Goldman Sachs Global Healthcare Conference be held?

The conference will be held in Rancho Palos Verdes, CA.

How can I access the live webcast of the Repare Therapeutics fireside chat?

The live webcast can be accessed in the Investor section of Repare Therapeutics' website.

What are the key products in Repare Therapeutics' pipeline?

Repare's pipeline includes camonsertib (RP-3500), a leading ATR inhibitor, and RP-6306, a PKMYT1 inhibitor.

What technology does Repare Therapeutics use for its drug development?

Repare utilizes its proprietary synthetic lethality approach and SNIPRx® platform for drug discovery.

Repare Therapeutics Inc. Common Shares

NASDAQ:RPTX

RPTX Rankings

RPTX Latest News

RPTX Stock Data

56.11M
38.71M
0.95%
83.73%
1.43%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
SAINT-LAURENT